Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 305 | 76 | 224 |
| Samples | 279 | 66 | 209 |
| Peptides | 231 | 45 | 187 |
Function
PPP1R15B · Protein phosphatase 1 regulatory subunit 15B
This gene encodes a protein phosphatase I-interacting protein that promotes the dephosphorylation of eukaryotic translation initiation factor 2A to regulate translation under conditions of cellular stress. The transcribed messenger RNA contains two upstream open reading frames (ORFs) that repress translation of the main protein coding ORF under normal conditions, while the protein coding ORF is expressed at high levels in response to stress. Continual translation of the mRNA under conditions of eukaryotic translation initiation factor 2A inactivation is thought to create a feedback loop for reactivation of the gene during recovery from stress. In addition, it has been shown that this protein plays a role in membrane traffic that is independent of translation and that it is required for exocytosis from erythroleukemia cells. Allelic variants of this gene are associated with microcephaly, short stature, and impaired glucose metabolism. [provided by RefSeq, Feb 2016].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000367188 | Q5SWA1 | 305 | 231 |
Gene Properties
Recurrent Mutations
All 231 amino-acid changes on canonical ENST00000367188 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PPP1R15B · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PPP1R15B – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 6/40 15% | 0/0 0% |
| Chordoma | 3/7 43% | 0/13 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Endometrial Carcinoma | 3/42 7% | 13/612 2% |
| Bladder Carcinoma | 2/58 3% | 16/956 2% |
| Melanoma | 4/210 2% | 24/1899 1% |
| Burkitts Lymphoma | 3/32 9% | 0/196 0% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 19/1390 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Colorectal Carcinoma | 6/143 4% | 26/3239 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 7/810 1% |
| Cervical Carcinoma | 2/35 6% | 2/422 0% |
| Neuroendocrine Tumour | 5/154 3% | 1/577 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Medulloblastoma | 0/0 0% | 3/450 1% |
| Kidney Carcinoma | 3/85 4% | 10/1862 1% |
| Hepatocellular Carcinoma | 1/46 2% | 14/2210 1% |
| Gastric Carcinoma | 0/74 0% | 12/1809 1% |
| Other Solid Cancers | 3/94 3% | 7/1515 0% |
| Breast Carcinoma | 5/144 3% | 14/3264 0% |
| Ovarian Carcinoma | 4/109 4% | 2/998 0% |
| Other Sarcomas | 0/69 0% | 4/699 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Biliary Tract Carcinoma | 0/54 0% | 5/950 1% |
| Pancreatic Carcinoma | 1/89 1% | 6/1611 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Esophageal Squamous Cell Carcinoma | 4/51 8% | 5/2550 0% |
| Glioma | 1/52 2% | 6/2127 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
Mutation Distribution
Where PPP1R15B is mutated · all tissues, split by cell line vs tissue
How many mutations in PPP1R15B were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 305 mutations in PPP1R15B
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|